Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders

Autores
Rey, María Verónica; Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; Rodriguez Elias, Fanny Elizabeth; Calderón, José; Arellano, Arturo; Pérez Lloret, Santiago
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Objectives The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients. Methods Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823). Results Movement disorders were observed in 5%, 9%, and 13% of patients in groups A to C, respectively (P < 0.001, χ2 for linear trend). A logistic multivariate analysis revealed that male sex (odds ratio = 2.26, 95% confidence interval = 1.13–4.49, P < 0.01), exposure to first-generation (vs second-generation) APDs (odds ratio = 5.71, 95% confidence interval = 2.08–15.66, P < 0.01), and exposure to lithium (odds ratio = 3.99, 95% confidence interval = 1.74–9.14, P < 0.01) were independently and significantly associated with MDs. Conclusions Male sex, use first-generation APDs, and exposure to lithium were associated with MDs in depression. Therefore, caution is advised with the use of these drugs in depressive patients. Prospective studies are needed to confirm these results.
Fil: Rey, María Verónica. Etymos Consulting Group; Argentina
Fil: Molina, Luis. Clínica de Especialidades Altamira; Nicaragua
Fil: Recinos, Byron. Universidad San Carlos de Guatemala; Guatemala
Fil: Paz, Bezner. Hospital Juan de Dios de San Pedro;
Fil: Rovelo, Mauricio. Instituto de Salud Mental; Honduras
Fil: Rodriguez Elias, Fanny Elizabeth. Colonia Médica; El Salvador
Fil: Calderón, José. Clínica de la Conducta; Panamá
Fil: Arellano, Arturo. Drugtech, Corporación Farmacéutica Recalcine; Costa Rica
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
Materia
ANTIPSYCHOTIC DRUGS
BIPOLAR DEPRESSIVE DISORDER
DRUG-INDUCED MOVEMENT DISORDERS
MAJOR DEPRESSIVE DISORDER
PHARMACOVIGILANCE
SCHIZOPRHENIA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/93985
Acceder
id CONICETDig_39c7ac33a63d14668dfd44125e53303a
oai_identifier_str oai:ri.conicet.gov.ar:11336/93985
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive DisordersRey, María VerónicaMolina, LuisRecinos, ByronPaz, BeznerRovelo, MauricioRodriguez Elias, Fanny ElizabethCalderón, JoséArellano, ArturoPérez Lloret, SantiagoANTIPSYCHOTIC DRUGSBIPOLAR DEPRESSIVE DISORDERDRUG-INDUCED MOVEMENT DISORDERSMAJOR DEPRESSIVE DISORDERPHARMACOVIGILANCESCHIZOPRHENIAhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Objectives The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients. Methods Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823). Results Movement disorders were observed in 5%, 9%, and 13% of patients in groups A to C, respectively (P < 0.001, χ2 for linear trend). A logistic multivariate analysis revealed that male sex (odds ratio = 2.26, 95% confidence interval = 1.13–4.49, P < 0.01), exposure to first-generation (vs second-generation) APDs (odds ratio = 5.71, 95% confidence interval = 2.08–15.66, P < 0.01), and exposure to lithium (odds ratio = 3.99, 95% confidence interval = 1.74–9.14, P < 0.01) were independently and significantly associated with MDs. Conclusions Male sex, use first-generation APDs, and exposure to lithium were associated with MDs in depression. Therefore, caution is advised with the use of these drugs in depressive patients. Prospective studies are needed to confirm these results.Fil: Rey, María Verónica. Etymos Consulting Group; ArgentinaFil: Molina, Luis. Clínica de Especialidades Altamira; NicaraguaFil: Recinos, Byron. Universidad San Carlos de Guatemala; GuatemalaFil: Paz, Bezner. Hospital Juan de Dios de San Pedro; Fil: Rovelo, Mauricio. Instituto de Salud Mental; HondurasFil: Rodriguez Elias, Fanny Elizabeth. Colonia Médica; El SalvadorFil: Calderón, José. Clínica de la Conducta; PanamáFil: Arellano, Arturo. Drugtech, Corporación Farmacéutica Recalcine; Costa RicaFil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; ArgentinaLippincott Williams2018-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/93985Rey, María Verónica; Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; et al.; Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders; Lippincott Williams; Clinical Neuropharmacology; 41; 5; 9-2018; 177-1800362-5664CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1097/WNF.0000000000000300info:eu-repo/semantics/altIdentifier/url/https://insights.ovid.com/crossref?an=00002826-201809000-00006info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-11-26T08:59:45Zoai:ri.conicet.gov.ar:11336/93985instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-11-26 08:59:46.11CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
title Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
spellingShingle Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
Rey, María Verónica
ANTIPSYCHOTIC DRUGS
BIPOLAR DEPRESSIVE DISORDER
DRUG-INDUCED MOVEMENT DISORDERS
MAJOR DEPRESSIVE DISORDER
PHARMACOVIGILANCE
SCHIZOPRHENIA
title_short Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
title_full Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
title_fullStr Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
title_full_unstemmed Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
title_sort Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
dc.creator.none.fl_str_mv Rey, María Verónica
Molina, Luis
Recinos, Byron
Paz, Bezner
Rovelo, Mauricio
Rodriguez Elias, Fanny Elizabeth
Calderón, José
Arellano, Arturo
Pérez Lloret, Santiago
author Rey, María Verónica
author_facet Rey, María Verónica
Molina, Luis
Recinos, Byron
Paz, Bezner
Rovelo, Mauricio
Rodriguez Elias, Fanny Elizabeth
Calderón, José
Arellano, Arturo
Pérez Lloret, Santiago
author_role author
author2 Molina, Luis
Recinos, Byron
Paz, Bezner
Rovelo, Mauricio
Rodriguez Elias, Fanny Elizabeth
Calderón, José
Arellano, Arturo
Pérez Lloret, Santiago
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ANTIPSYCHOTIC DRUGS
BIPOLAR DEPRESSIVE DISORDER
DRUG-INDUCED MOVEMENT DISORDERS
MAJOR DEPRESSIVE DISORDER
PHARMACOVIGILANCE
SCHIZOPRHENIA
topic ANTIPSYCHOTIC DRUGS
BIPOLAR DEPRESSIVE DISORDER
DRUG-INDUCED MOVEMENT DISORDERS
MAJOR DEPRESSIVE DISORDER
PHARMACOVIGILANCE
SCHIZOPRHENIA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Objectives The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients. Methods Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823). Results Movement disorders were observed in 5%, 9%, and 13% of patients in groups A to C, respectively (P < 0.001, χ2 for linear trend). A logistic multivariate analysis revealed that male sex (odds ratio = 2.26, 95% confidence interval = 1.13–4.49, P < 0.01), exposure to first-generation (vs second-generation) APDs (odds ratio = 5.71, 95% confidence interval = 2.08–15.66, P < 0.01), and exposure to lithium (odds ratio = 3.99, 95% confidence interval = 1.74–9.14, P < 0.01) were independently and significantly associated with MDs. Conclusions Male sex, use first-generation APDs, and exposure to lithium were associated with MDs in depression. Therefore, caution is advised with the use of these drugs in depressive patients. Prospective studies are needed to confirm these results.
Fil: Rey, María Verónica. Etymos Consulting Group; Argentina
Fil: Molina, Luis. Clínica de Especialidades Altamira; Nicaragua
Fil: Recinos, Byron. Universidad San Carlos de Guatemala; Guatemala
Fil: Paz, Bezner. Hospital Juan de Dios de San Pedro;
Fil: Rovelo, Mauricio. Instituto de Salud Mental; Honduras
Fil: Rodriguez Elias, Fanny Elizabeth. Colonia Médica; El Salvador
Fil: Calderón, José. Clínica de la Conducta; Panamá
Fil: Arellano, Arturo. Drugtech, Corporación Farmacéutica Recalcine; Costa Rica
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
description Objectives The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients. Methods Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823). Results Movement disorders were observed in 5%, 9%, and 13% of patients in groups A to C, respectively (P < 0.001, χ2 for linear trend). A logistic multivariate analysis revealed that male sex (odds ratio = 2.26, 95% confidence interval = 1.13–4.49, P < 0.01), exposure to first-generation (vs second-generation) APDs (odds ratio = 5.71, 95% confidence interval = 2.08–15.66, P < 0.01), and exposure to lithium (odds ratio = 3.99, 95% confidence interval = 1.74–9.14, P < 0.01) were independently and significantly associated with MDs. Conclusions Male sex, use first-generation APDs, and exposure to lithium were associated with MDs in depression. Therefore, caution is advised with the use of these drugs in depressive patients. Prospective studies are needed to confirm these results.
publishDate 2018
dc.date.none.fl_str_mv 2018-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/93985
Rey, María Verónica; Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; et al.; Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders; Lippincott Williams; Clinical Neuropharmacology; 41; 5; 9-2018; 177-180
0362-5664
CONICET Digital
CONICET
url http://hdl.handle.net/11336/93985
identifier_str_mv Rey, María Verónica; Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; et al.; Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders; Lippincott Williams; Clinical Neuropharmacology; 41; 5; 9-2018; 177-180
0362-5664
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1097/WNF.0000000000000300
info:eu-repo/semantics/altIdentifier/url/https://insights.ovid.com/crossref?an=00002826-201809000-00006
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Lippincott Williams
publisher.none.fl_str_mv Lippincott Williams
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1849873331261538304
score 13.011256

Publicaciones similares